Brief: Meridian Bioscience Receives Re-Authorization From FDA For Its Revogene® Sars-Cov-2 Molecular Assay
29/07/2022 14:27
July 29 (Reuters) - Meridian Bioscience Inc VIVO.O :
* MERIDIAN BIOSCIENCE RECEIVES RE-AUTHORIZATION FROM FDA FOR
ITS
REVOGENE® SARS-COV-2 MOLECULAR ASSAY
* MERIDIAN BIOSCIENCE INC - EXPECTS TO BEGIN SHIPPING THIS
PRODUCT
BEFORE END OF ITS FISCAL Q4, ENDING SEPTEMBER 30, 2022
Source text for Eikon: ID:nPn5CVfXPa
Further company coverage: VIVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VivoPower
See all newsBrief: Vivopower Signs Definitive Heads Of Agreement With Open Innovation Ai To Develop Secure Sovereign Ai Data Centers Across The Nordics, Mainland Europe, The GCC And Selective Countries In Asia
Brief: Vivopower Approves Independent Listing Of 2.2Gw Non-Nordic Ai Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control
Brief: Vivopower Secures Us$50 Million Pipe At Us$7.50 Conversion Price Per Share
Brief: Vivopower Shortlists Ai Tenants For 41.5Mw Norway Ai Data Center After Receiving Multiple Bids
Brief: Vivopower PLC Prequalifies 30 MW From Mo I Rana Data Center Into Statnett Reserve Markets